year and call Welcome Tara earnings operator. by Officer, Thanks, Financial fiscal I XXXX Chief Semb. am to quarter fourth on our our call. joined today’s everyone
factors XXXX, quarter quarter and for an our of operational Tara by revenue you our we fourth earnings will start we release detail, recent in then introduced results today. during I financial our a our in cover quick I to results as guidance that our as reviewing which update in discuss will the with well performance. financial to fourth months. progress fourth to provide of Then our what quarter will contributed intend Turning agenda and the today,
in I we will the outlook for our focus call XXXX before thoughts areas of some conclude open with on and key Q&A.
of results. with Let’s review get a fourth started quarter our revenue
quarter our Our to we the of range These decreased our provided XX% total below results the earnings low on in approximately were million. guidance end $XXX,XXX call. revenue $XX.X fourth year-over-year November
total partially XX% million. softer anticipated $X.X by was sales, performance Our revenue and than million Energy year-over-year XX% driven offset which expected Advanced than which to by better sales, $XX.X year-over-year decreased increased OEM to
device interruption to in our Looking at by impacted global sales business the in March performance be business Energy in Advanced related detail, the was products Energy the more to medical XXXX. our continued of of posted Advanced safety by FDA which communication,
Energy than continued Advanced the year-over-year sales driven throughout by to it of anticipated declines quarter, anticipated, both our impact the most sales of nearly fourth quarter, as the In we and we global generator disruption was global internationally. level While fourth relates higher decreased notably, Generators. domestically XX%
These moderated declines global sales. by a handpiece decrease in XX% were
Energy As to technology. generator business aspect of from the a has users prior safety new we discussed sales Advanced primarily have the of our impact are sales our reflection in notable This most seen quarters, communication. of
versus a pace sequential important increasing the is overall to than it recognize sales had guidance sales While assumed, trends demand global XX% on slower recovery nearly generator of our was improved that with in basis. QX generator
U.S. Advanced Advanced year-over-year. continued than generators more products of geographic had markets U.S. anticipated. our in by by in of region Energy of all to than detail, than our decreasing sales at Looking Advanced our In specifically, be Energy sales we more difficult XX% Generators by with more more XX% decreased the sales Energy year-over-year performance our
new effort has customers the reps understand continued more which help potential have our to to and our elongated of and time communication, required market sales technology, our find Given that historical communication related has efficacy the cycle. the safety the and safety confusion to in profile the been
remained generator which the base by initially customers success install sales was educating to While our in sales speaks since to base grow XXXX, our and year-over-year, both U.S. team impacted had safety new active to XX% our engaging in with we in pleased the has customers of total posted. U.S. install communication were and the
from Advanced by U.S. decreased as Energy XX% experience demand the Outside continued America. for sales key of than most we and to Latin notably countries, year-over-year in than generators Generators more distributors anticipated in weaker Europe our
pleased handpiece growth we demand in countries distributor see Europe markets While from in handpieces Latin resulted international anticipated we in stronger distributors varied were to international which year-over-year across several sales America, our handpiece and serve, demand QX. in for in than quarter APAC, the fourth in
of to recent operational two earnings fourth remained primary the Shifting discussion objectives our during in fourth our that quarter performance outlined the and focused months, team the on our recent on most calls. quarter we
distributors our and OUS to confusion clarify on focused existing safety U.S. customers potential with First related engaging our to communication. potential the we remained
and a severe As for or rhytides in in an skin obtained indication to an of and the wrinkles region. for procedures the clinical and specific use loose indication of appearance new treatment approve indications, we XXXX, the reminder, submental lax dermatological in two moderate neck to
FDA important XXX(k) continued With the ensure world with fourth over these outside overall of the during new as updates our Following marketing profile questions U.S. the communication. revisions related been of clearances, communicate the The our our and indirect work process two this the any to publications model. developments studies, clinical communication more commercial materials, their prolonged indication. issued our and backdrop, educational leveraging to and efficacy a given address understand and prospective receipt updated safety to safety each as to our has of quarter, by products, our XX reflect these safety the supported real clinical customers IDE evidence team
to to our we advanced topic the users safety in-person and of attend data to able opportunity us November and pleased any was supporting mind, directly potential misconceptions, meeting early were This communication, energy this address personally. Latin I the products. our clinical explain America provided real host in With clarify first with the world meeting which
also was – with also KOLs, opportunity interactive, region very panels included be of with peers. presentations a event providing to the and series customers which our discussion learn Latin from The America proved to our the event in the their
Overall, the meeting strong the and during contributing attended well our handpiece was very in productive America Latin fourth sales quarter.
secure we technology to our we respect our clearances primary our in objective, to procedures. continued related – With to to the XXX(k) strategy use regulatory Renuvion second of surgery advance cosmetic additional obtained
believe a XXX(k) clearance our of Renuvion FDA use indication quarter, following the clinical engaged tissues During obtain on submission remaining their for the receiving the specific of communication. handpiece indication for soft address subcutaneous with will for the this the liposuction. to the limitations feedback APR of fourth needed for the a team proposed safety where We coagulation
to and clearance response related received formal and the the via December. our feedback request of end which announced into at February FDA agency’s submitted the we on incorporated press pre-submission in This in for and was request submitted XXX(k) January feedback September We our X. release
of retrospective in world used APR as of of leveraging a XXX(k) data demonstrating were our analysis Renuvion including Our able the is we evidence, safety our clearance of request well chart from by following Renuvion clinical substantial data real liposuction from skin an following large procedures liposuction to study when IDE supported handpiece set the reviews. evidence as use conduct laxity, for
data XXX the data XXXX Our body. and treatment patients areas from set included more than of
liposuction or no to Importantly, demonstrated new this alone. real liposuction that when for liposuction was were to analysis compared review, our gathered there Renuvion evidence following for treatment increased data world procedures, in compared literature procedures, risks
fourth handpiece additional of and the tissue tissue, for related submitted the contraction indication quarter, XXX(k) soft needed the to including the also During APR subcutaneous our to for request obtain we completed clearance where on Renuvion an body. use of the an
as safety for On February pleased to were technology receive Energy and supporting regulatory products. used in recent year, clearance to effective further secure XXth, strong continue this indication effectiveness and soft use safe our past when were of to and our progress contract made We this has we Renuvion Advanced pleased our with the of team months, in we the tissue. demonstrating the clearances
operational like several the performance on to financial for In XXXX. position, Medical Apyx these share important improved made in have an to we efforts, addition fronts I'd progress to other update on
marketing During efforts quarter, continued Renuvion and of use two the for to to our related in launch the new secured sales their our that the teams commercial we prepare fourth indications for technology the clinical XXXX.
on that and our wrinkle each reduction January both As enable new procedures, pleased year. in to procedures a clinical the to our indications neck patients to in I performed these surgeons potential we both years for approximately market announce launch for began estimate contouring XXX,XXX Xrd. reminder, are U.S. very and we indications XXX,XXX technology am us two
In This introduced campaign, direct-to-consumer tandem brand first we Me. this with titled. launch, our is
are social campaign campaign supported brand of all a featuring platforms, digital and designed the dedicated patient-focused media Direct-to-Consumer initiatives website, benefits highlight and Renuvion a by of advertising awareness to nationwide raise technology. and our launch on Our multiple
been in we of we While series technology feedback we our In from television series, fourth in e-channel focused quarter patients the two launch, months during surgeons of series have to this popular Surgery. positive. received the pleased Awake cosmetic early launch, see TLC very and and Botched remain were the featured has advance on procedures also the
Console, commercialization Generator, One of Console. designing On front with Renuvion the Apyx for product team One of Apyx In preparations product our community. surgeon development new the the the closely we work members completed our the next-generation.
and goal was our ease the surgeon to use functionality, overall enhance of customers. Our for overarching experience
mind, measures for including of gas, and cloud parts features and sharing, that presets in the touchscreens, the an and gas connectivity, advanced in this specific and system diagnostics Apyx, capabilities enhancements, upgrade key remote monitors Console and logging intuitive, volume data, system With procedural usage. One adaptive body,
In is handpieces. of also to features, future One Apyx with these be compatible designed our generations addition to Renuvion
program Following all U.S. One January, now have existing our users. launch an is of in available late we introduced Apyx upgrade and the our U.S. for in the
progress in our product to addition fronts, sheet. regulatory income had development of recent progress and commercial, federal our IRS at ‘XX important tax January, of enhance were and made million XXXX, be our on that the examination balance refunds that have for approved least in completed ‘XX returns to notified Lastly, cash months tax and processed. our we we In the their $X.X new
await to the these continue receipt funds. We of
a million. with credit $XX $XX a announced we credit agreement senior February of line up and to of facility up five-year Financial for $XX to of On XXst, includes The facility million. Loan revolving secured million term new a MidCap up to a
and and On closing, balance At offices company of of we loan proceeds. approximately which entry located with million the filed facility $X proceeds the net Acquisitions condition. that our into our terms agreement, XXth, $X.XX disclosing gross sale a sheet, of March Under an property agreement, our X-K further to term Clearwater, building VK and leaseback Florida, one tranche us provided the for financial the in of the manufacturing LLC sold including million. houses our strengthens
commissions, as sale our the generation from subject million the $X.X XX diligence our closing transaction, expect borrowings million first-year revolver borrowings future. refunds, available our in profitability, the expected facility from the one cash in the of term to near to provide together future liquidity the sale achieve potential inspection agreement to $X and goals next and of sustainable our of customary is our from The our tranche and We period from to free tax generating of from we of due expense. growth our deposit work days. cash would approximately strong - million initiatives fund loan, ample net leaseback $X.X proceeds over the in the and believe receive rent cash flow sale of term on we Upon expenses the net transaction, longer-term loan, of and million with and $X.X term strategic of over proceeds
while we progress of than I customers. from aspects strategy back, has difficult seen across passion discussed. provided remain pleased continued our as the key achieved anticipated, for more ultimately challenging with to Stepping circumstances, our many notable technology Despite just XXXX we had have be our team we our
return our a ample the and towards to liquidity financial in in believe profile, achievements with strong the term important near strategic growth sales initiatives Apyx growth progress fund our profitability goals. position our driving We for term longer these to as Medical improvements we
but it to XXXX quarterly related results me financial a let to will discuss our Tara minute, I guidance. Tara? in XXXX priorities our and outlook turn and review over further first,
